AC
OCUL icon

Athanor Capital’s Ocular Therapeutix OCUL Stock Holding History

Athanor Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,644
Closed -$191K – 661
2021
Q1 		$191K Sell
11,644
-20,029
-63% -$386K ﹤0.01% 743
2020
Q4 		$656K Buy
+31,673
New +$470K 0.01% 411

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Athanor Capital's OCUL Position: Q2 2021 in Review

Athanor Capital sold out of Ocular Therapeutix (OCUL) in Q2 2021, closing a stake of 11,644 shares — an estimated $191K sold.

Athanor Capital first reported a position in OCUL in Q4 2020 and held it in 2 quarters. The position peaked at $656K in Q4 2020. 149 funds tracked by Wall St. Rank hold OCUL as of Q2 2021.

  • Athanor Capital reported no remaining Ocular Therapeutix position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 11,644 Ocular Therapeutix shares in Q2 2021, an estimated $191K.
  • Athanor Capital first reported a position in Ocular Therapeutix in Q4 2020 and held it in 2 quarters.
  • Athanor Capital's Ocular Therapeutix position peaked at $656K in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.